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Group B streptococcal early onset disease 
In most industrialized countries in the 1970s, the prevalence of group B strep-
tococcal (GBS) pneumonia, septicaemia and meningitis in young infants increased
dramatically. For more than 20 years, they have remained the major cause of
invasive bacterial infections in very young infants. 
Group B streptococcal early onset disease (EOD) typically occurs within the
first week of life. Almost 90% of babies with GBS disease present with signs of
systemic infection (fulminant pneumonia, septicaemia or, less often, meningitis)
at birth or within the first 24 hours of life.1,2 Despite intensive supportive care
and diagnostic and therapeutic advances, these infections are still associated with
high mortality (5–20%) and morbidity. More than 30% of infants recovering from
meningitis have long-term neurological sequelae: sight or hearing loss and
cerebral palsy.2–4 Group B streptococcal isolates are well distributed among the
various capsular serotypes, but most group B streptococci isolated from children
with meningitis belong to serotype III.
The group B streptococci that lead to colonization of infants at birth are
acquired through vertical transmission from the mother. Infants can become
colonized or infected in utero from ascending spread of group B streptococci, infec-
tion of the placental membranes and amniotic fluid by exposition to group B strep-
tococci or fetal aspiration of infected amniotic fluid.5,6 Alternatively, they may
become contaminated during their passage through the birth canal. Transmission
usually occurs after rupture of membranes, but it can also occur through intact
membranes. The magnitude of vaginal carriage of group B streptococci at the onset
of labour or rupture of membranes relates directly to the risk of vertical transmis-
sion and the likelihood of serious disease in the newborn.6 The skin or mucous
membranes of about 30–70% of neonates born to carriers of group B streptococci
become transiently colonized. Most infants remain asymptomatic, but 2–4% develop
a severe disease. If the vertical transmission of group B streptococci present in the
mother’s vagina at delivery substantially determines whether or not the newborn
will acquire the organism and be at risk of invasive disease, other maternal factors
are associated with an increased risk to develop EOD. These include low maternal
levels of anticapsular antibody homologous to the colonizing strain,7 labour and
delivery before 37 weeks of gestation, intrapartum temperature ≥38°C, rupture of
membranes sooner than 18 hours before delivery, a previous infant with invasive
GBS disease and GBS bacteriuria during the current pregnancy.8–11
The reported incidence of EOD (birth to seven days) is 0.5–4 cases per 1000
live births.2,9,12,13 Early onset disease accounts for about 80% of cases of neonatal
GBS disease.
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Colonization and infection with group B streptococci
Pregnancy-related colonization and infections 
The gastrointestinal tract is the natural reservoir for group B streptococci and is
the likely source of vaginal colonization.14 Vaginal colonization is unusual in child-
hood but becomes more common in late adolescence.12 Between 10% and 30% of
pregnant women are colonized with group B streptococci in the vagina or rectum.
This colonization is dynamic and can be chronic, transient or intermittent.
Colonization with group B streptococci usually is asymptomatic, and carriers need
to be identified through bacteriological screening of rectovaginal swabs. 
Group B streptococcal disease is also common in women during pregnancy and
in the postpartum period. Clinical manifestations include urinary tract infections
(usually asymptomatic bacteriuria but also pyelonephritis), intra-amniotic infections
(chorioamnionitis), endometriosis (often with bacteraemia), wound infections
associated with caesarean delivery or episiotomy, puerperal sepsis and occasion-
ally meningitis, septic thrombophlebitis or other serious complications. Group B
streptococcal disease probably causes 15–25% of puerperal fever with or without
bacteraemia.2,15 In some instances, GBS disease clearly causes stillbirths.
Neonatal group B streptococcal late-onset disease 
Group B streptococci cause late-onset disease (LOD) in young infants aged >1
week to ≥3 months. The clinical presentation, prognosis, epidemiological charac-
teristics and pathogenesis of GBS LOD differ from those of GBS EOD. Neonates
present with fever and clinical signs of meningitis or osteoarthritis, with or
without detectable bacteraemia. Most isolates from infants with GBS LOD are of
serotype III. Acquisition of group B streptococci by infants is more diverse and
results more often from horizontal transmission. The incidence is 0.3–1.8 (mean
0.5) per 1000 live births.4,12
Infections in adults
Since the 1990s, group B streptococci have also been recognized as important
pathogens that cause severe diseases in adults and are associated with high
mortality. Skin and soft tissue infections and bacteraemia are the most common
manifestations of invasive disease. The clinical spectrum also includes urosepsis,
pneumonia, peritonitis, meningitis, septic arthritis and endocarditis. The
incidence of GBS diseases in adults older than 20 years increases with age. Adults
with chronic illnesses, such as diabetes mellitus, liver failure or cancers, are at
higher risk for GBS severe infections. Death occurs in 16% of adults.
Belgian data
Belgium has not escaped the endemic situation of GBS infections observed in
most industrialized countries. Table 1 shows the main characteristics of the
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epidemiology of GBS and of neonatal infections reported in Belgium. These data
are based on different studies conducted by the Belgian Reference Laboratory for
GBS in collaboration with the epidemiological section of the Belgian Institute of
Public Health (ISP-WIV).13
In 1985 and 1990, two studies reported an incidence of three per 1000 live
births for GBS EOD, which represents the natural incidence of EOD before any
action to prevent the disease. In 1999, when some Belgian hospitals had imple-
mented a prevention strategy, the incidence was two per 1000 live births.
Another study that reviewed 130 cases of GBS EOD that had occurred in Belgium
in 1999–2000 reported that 60% of cases were not associated with any of the
additional maternal risk factors for EOD. According to reports from hospital
laboratories throughout the country, about 13–25% of pregnant women are
colonized with group B streptococci in the vagina or rectum.16
Between 1991 and 2001, GBS caused 37.9% of cases of early-onset sepsis and
meningitis. The second cause of EOD was E. coli (11.4 %). During the past decade,
a decline in the rate of infection with E. coli and other Gram-negative rods was
observed (, personal communication, ).17 
Prevention strategies
Recognition of the prevalence and severity of neonatal GBS disease has fuelled
intensive investigations aimed at elucidating the pathogenesis of GBS infections.
The continuing magnitude and severity of GBS disease and its attendant mortal-
ity and morbidity underscore the desirability of prevention methods. Two
approaches have been proposed: chemoprophylaxis and immunoprophylaxis.
Several strategies have been evaluated.
Immunization of women during or before pregnancy should be the most
promising, durable and cost-effective method for prevention of GBS EOD as well
as GBS LOD and peripartum maternal diseases. Unfortunately, such a strategy
remains investigational. Different types of vaccines are in development or under-
going clinical trials in healthy non-pregnant adults. 














T A B L E 1 Characteristics of group B streptococcal (GBS) early onset disease in
infants in Belgium, 1995–2001.13
Incidence in 1999 Two per 1000 live births
Mortality >14%





III 43% (the most frequent)
IV Very rare
V 9%
More than one maternal risk factor 40% of cases
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In the late 1980s, different methods of chemoprophylaxis were evaluated, and
several reports showed the efficacy of intrapartum penicillin G or ampicillin given
intravenously for prevention of GBS EOD.1,18,19 This approach prevents vertical
transmission of group B streptococci from colonized mothers and thus infection
of neonates with GBS EOD and also prevents maternal febrile morbidity.1,4 Both
β-lactams have been recommended, but penicillin is preferred for its narrower
spectrum. Other agents are recommended for women allergic to penicillin. 
Vertical transmission of group B streptococci has been shown to decrease
markedly within 2–4 hours of prophylaxis. An interval of at least four hours
from the start of prophylaxis to delivery is ideal. Expected efficacy is prevention
of 70–75% of cases, but a few cases of GBS EOD will continue to occur even
with ideal implementation. The challenge of such a strategy is identification of
targets for selective intrapartum chemoprophylaxis – that is women at risk of
having an infant with GBS EOD. In the 1990s, several organizations recom-
mended different approaches for the selection of women who should receive
chemopropylaxis. Such women could be identified on the basis of prenatal
screening cultures positive for group B streptococci or the presence of obstet-
ric risk factors. In 1996, the Centers for Diseases Control and Prevention
(CDC) in Atlanta, USA, recommended these two approaches to identify women
who should be given intrapartum chemoprophylaxis.12 The incidence of GBS
EOD has declined since these guidelines were released and the use of selective
intrapartum chemoprophylaxis has increased. In the USA, a 70% decrease in the
incidence was seen, but a plateau in the impact of prevention efforts seemed to
have been reached in 1999 with an incidence of 0.5 cases per 1000 live births.2,4
Different studies evaluated the efficacy of the two approaches, and, for differ-
ent reasons, they showed the superiority of the prenatal screening-based strat-
egy. An important CDC-sponsored multistate study published by Schrag in 2002
provided the first large-scale comparison of the two approaches.20 Surveillance
for GBS EOD was related to a population of more than 600,000 live births, and
a total of 312 cases were recorded. The analysis found that the screening
approach was 1.5 times more effective at preventing perinatal GBS disease than
the risk-based approach. The superiority of screening stemmed from two main
factors. First, 30–40% of women colonized with group B streptococci without
obstetric factors who were identified by screening were ignored by the risk-
based approach. Second, compliance differed between the two groups: women
with a prenatal screening culture positive for GBS were more likely to receive
intrapartum antibiotics than women with obstetric risk factors. Furthermore,
obstetric risk factors were also present in non-colonized women, so the risk
factor-based approach lacked specificity and unnecessarily exposed many
women to intrapartum chemoprophylaxis. 
In 2002, on the basis of the available evidence for a strong protective effect
of prenatal GBS screening compared with the risk-based approach, the CDC
issued revised guidelines for prevention of perinatal GBS EOD.21 These revised
guidelines have been endorsed by the American College of Obstetrics and
Gynecology (ACOG)11 and the American Academy of Pediatrics (AAP). A single
strategy is recommended: universal prenatal GBS screening at 35–37 weeks’
gestation and intrapartum chemoprophylaxis for pregnant women with GBS
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colonization or, when the result of screening culture is not known at the onset
of labour, on the basis of obstetric risk factors.11,21
At the same time, other public health organizations, such as in France and
Belgium, also evaluated the effectiveness and the feasibility of different strategies
rather similar to CDC’s guidelines.
Guidelines from the Belgian Superior Health Council: SHC 7721,
July 2003, Ministry of public health and social affairs3
Different Belgian studies related to obstetric practice, microbiological proce-
dures and paediatric management for the prevention of GBS EOD clearly demon-
strated that widely accepted updated guidelines based on evidence were
obviously needed to prevent GBS EOD.22–24
In 2002, a working group of experts and representatives of gynaecologists and
obstetricians, microbiologists and paediatricians from university and non-univer-
sity hospitals belonging equally to the French and Flemish communities was
appointed by the Superior Health Council (SHC) to review international and
Belgian studies and guidelines. The recommendations that resulted were the
matter of consensus within the working group and based on available evidence
and experts’ opinion. 
Belgian guidelines for the prevention of perinatal GBS infections were issued
by the SHC in July 2003.13 General and specific guidelines were proposed. These
guidelines should be known and implemented in routine practice by gynaecolo-
gists, obstetricians, microbiologists, paediatricians and neonatalogists. They are
very similar to the CDC’s revised 2002 guidelines21 except for some amendments
or added suggestions. The main recommendations are:
● Obstetricians, with the collaboration of supporting bacteriological laboratories
and midwives, should comply with the strategy illustrated in Figure 1. 
● The goal for prenatal screening cultures should be to predict the vaginal intra-
partum GBS colonization status. 
● The decision to give intrapartum antimicrobial prophylaxis (IAP) should be
guided by screening results. At the onset of labour or rupture of membranes,
IAP should be given to all women colonized with group B streptococci. Other
indications and conditions for IAP are described in Figure 1. 
For more specific conditions or more detailed descriptions, the full text is
available in English, Flemish or French on SHC’s website at
www.health.fgov.be/CSH_HGR/.13 Additional algorithms for the management of
threatened preterm delivery and women colonized with group B streptococci
due to undergo planned caesarean deliveries are also provided in the full text.
Prenatal screening for GBS
The sensitivity and specificity of antenatal cultures six or more weeks before
delivery for identifying the colonization status at delivery are rather low, and the
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results will not accurately predict this status. Predictive values increase as deliv-
ery nears, but so does the number of women who deliver before culture or
results are available.25 For the best compromise between prediction of coloniza-
tion and timing of screening, the guidelines advise the practitioner to obtain
cultures at 35–37 weeks’ gestation. According to numerous studies, careful
attention must address the anatomical sites swabbed and the precise bacterio-
logical methods used to enhance the accuracy of prenatal screening. The guide-
lines detail both topics. To increase the yield of group B streptococci and the
detection of very low inocula, lower vaginal and rectal swabs must be collected,
and cultured in a selective enrichment broth followed by subculture on to a
Granada-like agar is recommended. Granada medium agar allows easy identifica-
tion of group B streptococci on the basis of the production of a specific orange
pigment. The full procedure is provided in the SHC guidelines. Specific guidelines
for collection and transport of specimens for screening are summarized in Table
2.





Unless patient had a previous infant with GBS invasive disease
or GBS bacteriuria during the current pregnancy
or delivery occurs <37 weeks’ gestation*
! Facultative ! :
Intra-partum rapid GBS antigenic test**
Negative Positive
 1 maternal risk factor:
– Intrapartum fever 38°C***
– ROM 18 h
GBS Negative GBS Positive
NO YES




Recto-vaginal GBS screening culture at 35–37 weeks’ gestation for ALL
pregnant women
F I G U R E 1 Indications for intrapartum antibiotic prophylaxis to prevent perinatal
group B streptococcal (GBS) disease under a universal prenatal screening strategy.
Adapted from Belgian guidelines13
*An algorithm for prophylaxis of group B streptococci for patients in whom onset of labour or
rupture of amniotic membranes occurs before 37 weeks’ gestation and the risk of preterm delivery
is significant (as assessed by the clinician) is suggested in the guidelines.13
**Currently, only one test – the Strep B OIA (Thermo BioStar) – shows appropriate sensitivity and
specificity.
***If amnionitis is suspected, broad-spectrum antibiotic therapy that includes an agent known to be
active against group B streptococci should replace the GBS prophylaxis.
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For all pregnant women identified as carriers of group B streptococci, intra-
partum chemoprophylaxis must be scheduled. It is important to remember,
however, that antibiotics should not be given during pregnancy to treat GBS
colonization unless the pregnant women has a bacteriuria with group B strepto-
cocci. Such treatment is not helpful in eradicating GBS colonization or prevent-
ing perinatal GBS infections and, furthermore, is associated with adverse effects. 
Regimens for antimicrobial prophylaxis
To date, all human isolates of group B streptococci remain uniformly susceptible
to penicillin G and other members of the penicillin family. Penicillin is the first-
line antibiotic for intrapartum prophylaxis of GBS disease because of its narrow
spectrum of action and the resultant decreased potential for selection of resis-
tant strains and because of evidence of its efficacy. The recommended regimen
and alternatives for women allergic to penicillin are summarized in Table 3. 
35SECOND MEETING OF THE EUROPEAN INFECTION CONTROL ADVISORY PANEL
T A B L E 2 Obstetrician’s procedure for collecting specimens for prenatal screening
for GBS. Adapted from Belgian guidelines.13
When ● Collect specimen at 35–37 weeks’ gestation
Who ● All pregnant women at the time of pregnancy
Which site ● Vaginal swab: lower vagina 
● Rectal swab: through anal sphincter
Material ● One (or two) swab(s) for collection of both sites
placed in non-nutritive transport medium (eg Amies or
Stuart without charcoal)
Storage and transport ● Transfer specimens to laboratory within the day
● If any delay, refrigerate specimens (2–8°C) for no longer
than 48 hours
Requesting form ● Clearly request culture for GBS screening
















T A B L E 3 Recommended regimens for intrapartum antimicrobial prophylaxis for
prevention of perinatal GBS disease. 
Adapted from Belgian guidelines.13
Recommended regimen Regimen recommended for women allergic to penicillin
● 5 millions units penicillin ● Patients not at high risk for anaphylaxis:
G intravenously followed  2 g cefazoline intravenously followed by 1 g 
by 2.5 millions units ● Patients at high risk for anaphylaxis:
intravenously every eight  900 mg clindamycin intravenously every eight hours 
hours until delivery until delivery
 If group B streptococci resistant to clindamycin,
request microbiologist’s opinion
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Management of neonates at risk for group B streptococcal early-onset
disease 
Although the management of ill neonates with suspected infection and/or
neonates at high risk of infection is well defined, the management of asympto-
matic neonates is more problematic. Numerous unnecessary diagnostic evalua-
tions have been performed and too many useless antimicrobial treatments
initiated for fear of missing the first signs and symptoms of infection in infants
born to women who received antibiotics.26 An algorithm for the empirical
management of infants has been developed to minimize unnecessary investiga-
tions and antimicrobial treatments of infants whose mothers received intra-
partum prophylaxis to prevent GBS EOD or treat suspected chorioamnionitis.
The key parameters to take into account in this decision algorithm are gesta-
tional age (<35 weeks or >35 weeks), time between the beginning of antimicro-
bial prophylaxis and delivery (<4 hours or >4 hours) and the presence of some
obstetric risk factors. Stratified and defined diagnostic evaluations, their
expected values and the possible treatments are described in detail in the full
text of the Belgian guidelines.13 Unlike the CDC’s guidelines, the Belgian guide-
lines suggest a rational diagnostic approach as well as an empirical treatment to
be initiated at birth for asymptomatic infants at very high risk of developing a
severe GBS EOD – that is, infants born to women who were given antibiotics for
prolonged premature rupture of membranes or suspected chorioamnionitis.
In summary, for asymptomatic newborns with a gestational age ≥35 weeks
whose mother received a full IAP (≥4 hours), neither diagnostic evaluation nor
empirical antimicrobial prophylaxis is required. Empirical treatment and evalua-
tion for sepsis are recommended, however, for symptomatic infants with
suspected sepsis and neonates at very high risk of having GBS EOD. For all other
conditions, rational diagnostic evaluations are suggested.13 Paediatricians should
be told which strategy was used, so they can optimally manage newborns. 
Adverse and unintended consequences
Even if the guidelines issued by CDC or the Belgian SHC are currently the most
effective to prevent GBS EOD, areas of concern have accompanied these guide-
lines and are still being debated. More than 20% of women receive antibiotics
during labour, and antibiotics can have adverse and unintended effects.27 The most
important are mild allergic reactions, anaphylaxis and selection of antimicrobial
resistant pathogens, or the antibiotics could affect the incidence of EOD with
organisms other than group B streptococci. 27 Although penicillin allergies occur
and the risk of anaphylaxis exists, very few allergic events have been reported
since the release of the CDC’s 1996 guidelines,28 and they are greatly offset by
reductions in the incidence of maternal and neonatal invasive GBS disease.20
Among the unintended consequences of an increased use of intrapartum
antibiotics is the potential increased incidence or resistance in non-GBS early-
onset pathogens (Enterobacteriaceae, ampicillin-resistant E. coli, etc). Most
studies, including population-based multicentre studies, have found stable or
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decreasing rates in non-GBS early-onset sepsis during a period of increasing use
of intrapartum antibiotic prophylaxis for group B streptococci.21 The rare
reported increases in antibiotic-resistant early-onset infections in a few studies
are not of sufficient magnitude to outweigh the benefits of intrapartum antibiotic
prophylaxis. To assure early detection of increases in the rate of disease or
deaths caused by organisms other than GBS, our surveillance system of neonatal
sepsis by a network of sentinel laboratories must be maintained.
Effectiveness of the recommended strategy 
Comparison of cost-effectiveness: screening-based approach versus risk
factor-based approach 
Although there might be some fear that the screening-based option will lead to
more women being treated, the numbers will be the same for both options if all
risks are effectively considered. Direct expenses before delivery of course are
higher in the screening-based option and are related to prenatal cultures and the
amount of intrapartum prophylaxis given to prevent a case of GBS EOD. When
direct and indirect costs associated with a case are considered, however, the
percentage of prevented cases is much higher with the screening-based approach,
which makes this option more cost-effective than the risk-based approach.29 In a
nice mathematical model of the American population, Benitz, from the Stanford
University School of Medicine, clearly showed the superiority of the screening-
based approach. A rough simulation applied to Belgian epidemiology and costs
reaches the same conclusion. 
Encouraging results of effectiveness in Belgium
For 10 years, laboratories belonging to the Belgian surveillance network of
sentinel laboratories have sent all strains of group B streptococci isolated from
invasive infections plus clinical data to the Belgian reference laboratory for group
B streptococci. On the basis of cases of early and late onset neonatal disease
reported per year from 1999 to 2004, an increase of the ratio of LOD:EOD has
been observed: 0.16 in 1999 to 0.52 in 2004.30 The number of cases of GBS LOD
remains quite stable, but the number of cases of EOD is decreasing (Figure 2).
These observations should be confirmed for 2005–06, as the Belgian guidelines
for prevention of GBS perinatal disease are now implemented in most delivery
facilities and laboratories. With the policy chosen in Belgium, further reduction
of the cases of GBS EOD is expected. 
Future prevention strategy
While effective and safe vaccines are awaited, other approaches should be
designed and evaluated. 
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Intrapartum screening for group B streptococci
Use of a rapid screening test performed on a vaginal swab collected at the onset
of labour or at the time of rupture of the membranes should more accurately
identify women at risk of giving birth to a neonate with GBS EOD and thus
substantially reduce unnecessary intrapartum antibioprophylaxis. A sensitive and
specific test will decrease the numbers of false negatives and false positives seen
with prenatal screening or the risk-based approach, but its turnaround time
should not exceed one hour or too many women identified as GBS carriers will
not receive adequate intrapartum chemoprophylaxis before delivery (>4 hours).
Furthermore, it should be easy-to-use and convenient for integration into a
laboratory 24 hours a day, seven days a week. 
Recently, real-time polymerase chain reaction (PCR) tests for detection of
group B streptococci have been evaluated and are very promising. The most
recent in this category is the GBS GeneXpert test from Cepheid, which is a
sophisticated genetic tool designed for fully automated detection in about one
hour from an unprocessed vaginal swab to a result. New clinical trials are needed
to confirm the expected superiority of a strategy that uses such tests. 
Vaginal disinfection approach
Several studies, particularly from northern Europe, showed that vaginal douching
with chlorhexidine during labour reduced both maternal and early neonatal infec-
tious morbidity associated with group B streptococci.31,32 Other studies,





























F I G U R E 2 Number of cases of group B streptococcal (GBS) early-onset disease
(EOD) and late-onset disease (LOD) declared per year to the reference laboratory for
group B streptococci by the Belgian surveillance network of sentinel laboratories. SHC,
definition to be included
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however, did not demonstrate the advantages of this simple, cheap and harmless
method. These conflicting results were related to different protocols, concen-
trations, volumes and forms of chlorhexidine. 
Evaluation of an approach that combines vaginal douching with chlorhexidine
during labour for women without obstetric risks with intrapartum antimicrobial
prophylaxis for GBS carriers with obstetric risk factors will soon start with two
trials – one in the obstetrics department of the University Hospital of Liege,
Belgium, and the second in the University Hospital of Leon, Nicaragua. While
maintaining effectiveness at preventing neonatal GBS EOD and maternal morbid-
ity, this strategy should significantly reduce antibiotic prophylaxis and should be
effective even for women not screened during pregnancy or for whom screening
results are not available.
Conclusion
The Belgium group of experts of the SHC recommended intrapartum antimicro-
bial prophylaxis to prevent neonatal GBS EOD based on a universal prenatal
screening for GBS. On the basis of evidence, this is currently the most effective
method to prevent neonatal GBS EOD and related maternal morbidity. These
guidelines are considered as an interim policy until GBS vaccines achieve licence. 
Even with ideal implementation, cases of GBS EOD will continue to occur.
The goal is a reduction of 70% of cases, which equates to 300 cases per year in
Belgium. For ideal implementation, all means of improving collaboration and
communication between gynaecologists, bacteriologists and paediatricians must
be used. Another key for success is the integration of these recommendations in
to the routine management of women and neonates during pregnancy and at
delivery without incurring excessive costs or increased workload. 
Many details of the proposed strategies are important for optimal efficacy and
minimal adverse effects. Conditions for prenatal screening are crucial to reach
satisfactory predictive values of the GBS colonization status at delivery, as are
the means for reporting and communicating those screening results. 
In the near future, evaluation of new strategies, such as the use of rapid, real-
time PCR testing for intrapartum screening or vaginal douching with chlorhexi-
dine during labour, could lead to a revision of the current recommendations.
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Discussion
E G I L L I N G A A S : Intravaginal chlorhexidine may also prevent neonatal HIV
infection.
P I E R R E T T E M E L I N : It may possibly also prevent herpes – a colleague is
currently evaluating prevention of viral infections.
E G I L L I N G A A S : Does your colleague use neutralizer, which could risk a
false-negative culture, when taking cultures from neonates?
P I E R R E T T E M E L I N : I am not familiar with this aspect of the protocol.
R I C H A R D H I L L : Does intravaginal douching with chlorhexidine have side-
effects?
P I E R R E T T E M E L I N : It does not seem to have side-effects, and none have
been reported in the papers seen thus far.
E G I L L I N G A A S : What is your current regimen for empirical therapy for
newborns with symptoms of invasive infection after intrapartum penicillin? Do you
use penicillin, ampicillin or something else?
P I E R R E T T E M E L I N : We use ampicillin as the β-lactam but in combination
with an aminoglycoside. After 48 hours (once laboratory results are available)
penicillin can be given for group B streptococci. For GBS bacteraemia, we recom-
mend a course of 10 days but the duration of treatment is longer (at least two
weeks) for meningitis. 
E G I L L I N G A A S : Is neonatal Klebsiella infection a potential side-effect of
ampicillin?
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P I E R R E T T E M E L I N : Reference laboratories and a system of sentinel labora-
tories report all neonatal infections that occur during the first month of life. We see
very few cases of infection with Klebsiella. Over the last three years, we have seen
a decrease in all Gram-negative pathogens, an increase in S. aureus and a slight
increase in cases of group A streptococci in some centres.
P E T E R H E E G : How do you give the chlorhexidine and at what concentration?
P I E R R E T T E M E L I N : We give 120 ml of 0.2% aqueous solution (made up by
the pharmacy) via a catheter with a large syringe every six hours. The catheter is
withdrawn slowly as the chlorhexidine begins to flow. The solution remains in situ.
We have tried a gel, but it does not work. The concentration of 0.2% was decided
after literature review and discussions with Dr Pedersen.
R I C H A R D H I L L : Is there any value in using aqueous chlorhexidine to disin-
fect the skin of newborn babies?
P I E R R E T T E M E L I N : I do not know at the moment, but we are just complet-
ing a full review of the literature.
R I C H A R D H I L L : Have you studied the sites of colonization in newborn
babies?
P I E R R E T T E M E L I N : We have sampled the ears, throat, umbilicus and
sometimes groin in large epidemiological studies. One to multiple sites can be
colonized and the intensity of colonization also varies. 
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